Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Allergan will pay $250 million up front and up to $1.3 billion more in milestone payments over 15 years for rights to the AstraZeneca anti-IL-23 monoclonal antibody MEDI2070. AstraZeneca will pay one-third of the money it receives to Amgen, its partner in developing MEDI2070. The antibody is in Phase IIb clinical trials for treating Crohn’s disease and is ready to enter Phase II trials for ulcerative colitis. AstraZeneca says the target diseases fall outside its focus areas.
This article has been sent to the following recipient: